http://www.biospectrumasia.com/content/210911JPN17141.asp
Takeda Pharmaceutical announced that it launched LIOVEL, a fixed dose combination tablet of NESINA (generic name: alogliptin) and ACTOS (generic name: pioglitazone HCl) for treatment of type 2 diabetes in Japan.
LIOVEL is a tablet taken orally once daily and has two dosage strengths, “LIOVEL LD” and “LIOVEL HD” which contain 25mg alogliptin /15mg pioglitazone, and 25mg alogliptin /30mg pioglitazone respectively.
Takeda Pharmaceutical announced that it launched LIOVEL, a fixed dose combination tablet of NESINA (generic name: alogliptin) and ACTOS (generic name: pioglitazone HCl) for treatment of type 2 diabetes in Japan.
LIOVEL is a tablet taken orally once daily and has two dosage strengths, “LIOVEL LD” and “LIOVEL HD” which contain 25mg alogliptin /15mg pioglitazone, and 25mg alogliptin /30mg pioglitazone respectively.